Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL

Rachel M. Koldej, Allison Barraclough, Huw Morgan, Sze Ting Lee, Nicholas Holzwart, Minu Koshy, Charmaine Smith, Geoffrey Chong, Michael Gilbertson, Colm Keane, Denise Lee, Leonid Churilov, David S. Ritchie, Eliza A. Hawkes

Blood Neoplasia (2025) 2 (4): 100168.

https://doi.org/10.1016/j.bneo.2025.100168

Published: 2025

Includes: Supplemental data

Journal Articles

Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy

Chathuri Abeyakoon, Sita Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood Neoplasia (2025) 2 (4): 100164.

https://doi.org/10.1016/j.bneo.2025.100164

Published: 2025

Journal Articles

Bendamustine switches TNF receptor superfamily signal from a survival to a death signal in B-cell lymphomas

Kensuke Nakao, Hiroshi Arima, Yui Arakawa, Tomoyasu Jo, Yujuan Guo, Iroha Morita, Tomohiro Taya, Toshio Kitawaki, Akifumi Takaori-Kondo, Momoko Nishikori

Blood Neoplasia (2025) 2 (4): 100157.

https://doi.org/10.1016/j.bneo.2025.100157

Published: 2025

Includes: Supplemental data

Journal Articles

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia

Blood Neoplasia (2025) 2 (4): 100160.

https://doi.org/10.1016/j.bneo.2025.100160

Published: 2025

Includes: Supplemental data

Journal Articles

Current landscape of frontline and relapsed follicular lymphoma trials

Lawrence Cheng Kiat Ng, Carla Casulo

Blood Neoplasia (2025) 2 (4): 100131.

https://doi.org/10.1016/j.bneo.2025.100131

Published: 2025

Journal Articles

IgA or IgM MGUS less than 1.0 g/dL is at low risk of progression to neoplasm

Ashok P. Pai, Lue-Yen Tucker, David M. Baer

Blood Neoplasia (2025) 2 (4): 100140.

https://doi.org/10.1016/j.bneo.2025.100140

Published: 2025

Includes: Supplemental data

Journal Articles

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence

Pin Lu, Carrie A Franzen, Aldana Vistarop, Andrey Efimov, SK Abrar Shahriyar, Shengchun Wang, Shilpa Rao, Marcus Messmer, Shazia Nakhoda, Edna Cukierman, Shuo Ma, Janusz Franco-Barraza, Juehua Gao, Y. Lynn Wang

Blood Neoplasia (2025) 2 (4): 100142.

https://doi.org/10.1016/j.bneo.2025.100142

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

Yoshito Nishimura, Yiqun Han, Nadia Toumeh, Guneet Janda, Yu Fujiwara, Urshila Durani, Grzegorz S. Nowakowski, Jonas Paludo, Stephen M. Ansell, Jithma P. Abeykoon

Blood Neoplasia (2025) 2 (3): 100134.

https://doi.org/10.1016/j.bneo.2025.100134

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, Emma Berggren Dall, Stine Rasch, Mette Johansen, Simon Husby, Mikkel Runason Simonsen, Michael Roost Clausen, Thomas Stauffer Larsen, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Mats Jerkeman, Christian Bjørn Poulsen, Laura Mors Haunstrup, Peter Brown, Tarec Christoffer El-Galaly, Kirsten Grønbæk

Blood Neoplasia (2025) 2 (3): 100128.

https://doi.org/10.1016/j.bneo.2025.100128

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Frederique St-Pierre, Stephen M. Broski, Zequn Sun, Masha Kocherginsky, Betsy LaPlant, Matthew J. Maurer, Andrew Quon, Lucia Baratto, Hatice Savas, Lale Kostakoglu, Jane N. Winter, Thomas E. Witzig, Brad Kahl, Andrew M. Evens, Leo I. Gordon

Blood Neoplasia (2025) 2 (3): 100113.

https://doi.org/10.1016/j.bneo.2025.100113

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma

Nikita K. Dave, Veronica Carvajal, Alex C. Watts, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Wei-Ting Hwang, Daniel J. Landsburg, Sunita D. Nasta

Blood Neoplasia (2025) 2 (3): 100102.

https://doi.org/10.1016/j.bneo.2025.100102

Published: 2025

Includes: Supplemental data

Journal Articles

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

Emil Ramsø Kyvsgaard, Trine Lønbo Grantzau, Mia Dahl Sørensen, Michael Boe Møller, Lene Dissing Sjø, Morten Grauslund, Trine Trab, Linea Cecilie Melchior, Lærke Sloth Andersen, Caroline Riley, Carsten U. Niemann, Jacob Haaber, Thomas Stauffer Larsen, Michael Roost Clausen, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood Neoplasia (2025) 2 (3): 100096.

https://doi.org/10.1016/j.bneo.2025.100096

Published: 2025

Includes: Supplemental data

Journal Articles

Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma

Kavindra Nath, Pradeep K. Gupta, Shengchun Wang, Alexander A. Shestov, Neil Sen, Shilpa Rao, Stepan Orlovskiy, Cosimo Lobello, David Rushmore, Fernando Arias-Mendoza, Johnvesly Basappa, David S. Nelson, Mariusz A. Wasik

Blood Neoplasia (2025) 2 (3): 100105.

https://doi.org/10.1016/j.bneo.2025.100105

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis

Dai Chihara, Shibing Yang, Savreet Bains Chawla, Guihua Zhang, Anthony Wang, Junhua Yu, Donald Arnette, Fernando Rivas Navarro, Julie Blaedel, Alex Mutebi

Blood Neoplasia (2025) 2 (2): 100080.

https://doi.org/10.1016/j.bneo.2025.100080

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study

Blood Neoplasia (2025) 2 (1): 100063.

https://doi.org/10.1016/j.bneo.2024.100063

Published: 2025

Includes: Supplemental data

Journal Articles

Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis

Rodrigo Fonseca, Alex J. Liu, Blake T. Langlais, Diana Almader-Douglas, Holenarasipur R. Vikram, Talal Hilal

Blood Neoplasia (2025) 2 (1): 100061.

https://doi.org/10.1016/j.bneo.2024.100061

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi, Ryota Chijimatsu, Yusuke Naoi, Yoshihiro Otani, Ryo Mizuta, Kentaro Fujii, Joji Ishida, Hiroyuki Murakami, Hideki Ujiie, Kazuhiro Ikeuchi, Tomohiro Urata, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Nobuharu Fujii, Ken-ichi Matsuoka, Yasuharu Sato, Yoshinobu Maeda, Daisuke Ennishi

Blood Neoplasia (2025) 2 (1): 100058.

https://doi.org/10.1016/j.bneo.2024.100058

Published: 2025

Includes: Supplemental data

Journal Articles

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Swaminathan P. Iyer, Shaker Dakhil, Michi M. Shinohara, Jasmine Zain, Mark Acosta, Francine Foss

Blood Neoplasia (2024) 2 (1): 100055.

https://doi.org/10.1016/j.bneo.2024.100055

Published: 2024

Journal Articles

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai

Blood Neoplasia (2024) 2 (1): 100053.

https://doi.org/10.1016/j.bneo.2024.100053

Published: 2024

Includes: Supplemental data

Journal Articles

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Lawrence A. Stern, Vibhuti Vyas, Laura Lim, Christian Huynh, Ryan Urak, Ruby Espinosa, Zhiqiang Wang, Michalina Silva Thiel, John C. Williams, Stephen J. Forman, Christine E. Brown, Xiuli Wang

Blood Neoplasia (2024) 1 (4): 100048.

https://doi.org/10.1016/j.bneo.2024.100048

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL

Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy

Bendamustine switches TNF receptor superfamily signal from a survival to a death signal in B-cell lymphomas

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia

Current landscape of frontline and relapsed follicular lymphoma trials

IgA or IgM MGUS less than 1.0 g/dL is at low risk of progression to neoplasm

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies

Magnetic resonance spectroscopy–based detection of response to therapy targeting glutaminolysis in lymphoma

Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis

Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study

Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only